Juan Manuel Tiraboschi, PhD

Bellvitge University Hospital, Spain

Disclosure(s): Gilead Sciences: Advisor/Consultant, Grant/Research Support; Janssen: Advisor/Consultant, Grant/Research Support; MSD: Advisor/Consultant, Grant/Research Support; ViiV Healthcare: Advisor/Consultant, Grant/Research Support

Poster(s):

• 1251 - 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET